OR WAIT null SECS
June 11, 2021
Researchers from the Chalmers University of Technology and AstraZeneca have developed a new method of detecting and testing lipid nanoparticles.
June 03, 2021
The emergence of new biotherapeutics is both the driver and result of innovative drug development technologies.
In the present investigation, the fixed-dose combination (FDC) tablet of Atorvastatin calcium and Ezetimibe was prepared by a quality-by-design approach using two-level factorial design.
Particle engineering is a vital tool in overcoming many formulation challenges, and technological advances are enabling developers to achieve the full potential of pipeline molecules.
May 03, 2021
Vaccine development is inherently challenging; however, in light of the COVID-19 pandemic, innovations have been prioritized, leading to accelerated development processes.
April 22, 2021
DFE’s new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers high-quality excipient technology and services.
April 16, 2021
Biogen UK has announced that the UK’s MHRA and the EC have granted marketing authorization for the subcutaneous (SC) formulation of Tysabri (natalizumab).
April 15, 2021
This new technology could eliminate the need for cold chain storage, transport, and distribution of temperature-sensitive molecules.
April 03, 2021
Topical drugs are attractive to patients, but these complex products pose challenges for formulators.
Accelerated formulation strategies are a useful tool to reduce development timelines and cost, but key priorities must be considered early on to ensure success.